Aliases & Classifications for Scotoma

MalaCards integrated aliases for Scotoma:

Name: Scotoma 12 77 45 15
Generalized Visual Field Contraction or Constriction 12
Sector or Arcuate Visual Field Defects 12
Enlarged Paracaecal Scotoma 12
Scotoma of Blind Spot Area 12
Blind Spot Area Scotoma 12
Enlarged Angioscotoma 12
Enlarged Blind Spot 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9335
ICD9CM 36 368.42 368.44
MeSH 45 D012607
SNOMED-CT 69 33970004
ICD10 34 H53.42 H53.45

Summaries for Scotoma

MalaCards based summary : Scotoma, also known as generalized visual field contraction or constriction, is related to optic atrophy 1 and stargardt disease. An important gene associated with Scotoma is MT-ND4 (Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 4). The drugs Nifedipine and Labetalol have been mentioned in the context of this disorder. Affiliated tissues include eye, pituitary and testes.

Wikipedia : 77 A scotoma is an area of partial alteration in the field of vision consisting of a partially diminished... more...

Related Diseases for Scotoma

Diseases related to Scotoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Related Disease Score Top Affiliating Genes
1 optic atrophy 1 32.2 DNM1L OPA1
2 stargardt disease 29.8 ABCA4 EYS
3 optic nerve disease 29.0 DNM1L MT-ND4 MT-ND5 OPA1 TMEM126A
4 optic atrophy 5 11.2
5 cone-rod dystrophy 2 11.1
6 mohr-tranebjaerg syndrome 11.1
7 birdshot chorioretinopathy 11.1
8 optic atrophy 7 with or without auditory neuropathy 11.1
9 macular degeneration, age-related, 1 10.4
10 low tension glaucoma 10.3
11 neuritis 10.2
12 strabismus 10.2
13 suppression amblyopia 10.2
14 amblyopia 10.2
15 macular holes 10.1
16 spastic paraplegia 7, autosomal recessive 10.1 MT-ND4 OPA1
17 usher syndrome type 2 10.1 EYS OPA1
18 yemenite deaf-blind hypopigmentation syndrome 10.1
19 optic neuritis 10.1
20 acute retrobulbar neuritis 10.1
21 mechanical strabismus 10.1
22 headache 10.1
23 leber optic atrophy 10.0 MT-ND4 MT-ND5
24 deafness, nonsyndromic sensorineural, mitochondrial 10.0 MT-ND4 MT-ND5
25 retinitis pigmentosa 19 10.0 ABCA4 KCNMA1
26 systemic lupus erythematosus 10.0
27 retinal detachment 10.0
28 cataract 10.0
29 open-angle glaucoma 10.0
30 telangiectasis 10.0
31 uveitis 10.0
32 adenoma 10.0
33 lupus erythematosus 10.0
34 pathologic nystagmus 10.0
35 anterior uveitis 10.0
36 macular telangiectasia type 2 10.0
37 myoclonic epilepsy associated with ragged-red fibers 10.0 MT-ND4 MT-ND5
38 familial colorectal cancer 10.0 MT-ND4 MT-ND5
39 glaucoma, primary open angle 9.9 ABCA4 MVD
40 cranial nerve disease 9.9 DNM1L MT-ND4 MT-ND5
41 mitochondrial metabolism disease 9.9 MT-ND4 MT-ND5 OPA1
42 optic disk drusen 9.9
43 leber hereditary optic neuropathy 9.9 MT-ND4 MT-ND5 OPA1
44 astigmatism 9.8
45 hepatitis c virus 9.8
46 hepatitis 9.8
47 retinal vein occlusion 9.8
48 sinusitis 9.8
49 cytomegalovirus retinitis 9.8
50 migraine with aura 9.8

Graphical network of the top 20 diseases related to Scotoma:



Diseases related to Scotoma

Symptoms & Phenotypes for Scotoma

Drugs & Therapeutics for Scotoma

Drugs for Scotoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifedipine Approved Phase 4 21829-25-4 4485
2
Labetalol Approved Phase 4 36894-69-6 3869
3
Methyldopa Approved Phase 4 555-30-6 38853
4
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
5 Adrenergic beta-Antagonists Phase 4
6 Peripheral Nervous System Agents Phase 4,Not Applicable
7 Hormones Phase 4,Phase 3
8 Autonomic Agents Phase 4,Not Applicable
9 Neurotransmitter Agents Phase 4,Not Applicable
10 Sympathomimetics Phase 4,Not Applicable
11 Adrenergic Agents Phase 4,Not Applicable
12 Antihypertensive Agents Phase 4
13 Adrenergic Antagonists Phase 4
14 Vasodilator Agents Phase 4
15 Adrenergic alpha-1 Receptor Antagonists Phase 4
16 Tocolytic Agents Phase 4
17 Adrenergic Agonists Phase 4
18 Adrenergic alpha-2 Receptor Agonists Phase 4
19 calcium channel blockers Phase 4
20 Sympatholytics Phase 4
21 Adrenergic alpha-Agonists Phase 4
22 Adrenergic alpha-Antagonists Phase 4
23 Calcium, Dietary Phase 4
24
Ranibizumab Approved Phase 3,Phase 1,Phase 2 347396-82-1 459903
25
Bevacizumab Approved, Investigational Phase 3 216974-75-3
26
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
27 Angiogenesis Modulating Agents Phase 3,Phase 1,Phase 2,Not Applicable
28 Angiogenesis Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
29 Antineoplastic Agents, Immunological Phase 3
30 Immunosuppressive Agents Phase 3
31 Triamcinolone hexacetonide Phase 3
32 Anti-Inflammatory Agents Phase 3
33 glucocorticoids Phase 3
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
35 triamcinolone acetonide Phase 3
36 Hormone Antagonists Phase 3
37 Immunologic Factors Phase 3
38 Triamcinolone diacetate Phase 3
39 Antibodies Phase 3
40 Immunoglobulins Phase 3
41 Immunoglobulin Fab Fragments Phase 3
42
Idebenone Approved, Investigational Phase 2 58186-27-9
43
Imidacloprid Vet_approved Phase 2 105827-78-9 86418
44 Trace Elements Phase 2
45 Nutrients Phase 2
46 Antioxidants Phase 2
47 Ubiquinone Phase 2
48 Protective Agents Phase 2
49 Micronutrients Phase 2
50 Vaccines Phase 1

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 Early Vascular Adjustments During Hypertensive Pregnancy Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
2 Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Unknown status NCT01255774 Phase 3 ranibizumab
3 Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions Unknown status NCT01418820 Phase 2, Phase 3
4 Bevacizumab Versus Ranibizumab for Diabetic Retinopathy Completed NCT00545870 Phase 3 bevacizumab;Ranibizumab
5 Low Vision Depression Prevention Trial for Age Related Macular Degeneration Completed NCT00769015 Phase 3
6 Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone Completed NCT00685100 Phase 3
7 A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion Completed NCT01889251 Phase 3 Ocriplasmin;Sham injection
8 A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Terminated NCT02247479 Phase 3 Lampalizumab
9 Scotoma Reduction in AMD Patients Treated With Ranibizumab Completed NCT00467935 Phase 1, Phase 2 intravitreal injection Lucentis (ranibizumab)
10 Evaluation of Eye Movement Tracking Systems for Visual Rehabilitation Completed NCT00013429 Phase 2
11 Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation Completed NCT00971464 Phase 2
12 Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial) Completed NCT00504400 Phase 2 Intravitreal injection ranibizumab
13 Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy Completed NCT00747487 Phase 2 Idebenone;Placebo
14 Clinical Trial on Remote Ischemic Conditioning and Hypertension(HOPE) Not yet recruiting NCT03566654 Phase 2
15 Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) Completed NCT01327911 Phase 1
16 Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients Unknown status NCT00902109
17 Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter Unknown status NCT01068938
18 Bipolar Radiofrequency Ablation Plus Argon Beam Coagulator Ablation for Atrial Fibrillation Unknown status NCT02424110 Not Applicable
19 Clinical Study of LPI With Different Laser Wavelengths Unknown status NCT02901730 Not Applicable
20 Clinical Study of LPI on Different Sites of Iris Unknown status NCT02870504 Not Applicable
21 Oxidative Stress and Endothelial Function in Pregnancy Complications Unknown status NCT02603913
22 Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas Completed NCT01691027 Not Applicable
23 A Study to Determine the Location of the Blind Spot and the Macula-disc Centre Distance on a Fundus Photograph Completed NCT01843582
24 Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema Completed NCT02457884 Not Applicable
25 The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy Completed NCT00921427 Early Phase 1
26 Evaluation of Near Visual Acuity With ODYSIGHT, a Smartphone Based Medical App in Comparison to a Standardized Method Completed NCT03457441 Not Applicable
27 Sparing of the Fovea in Geographic Atrophy Progression Completed NCT02332343
28 Detection of Topographic Residual Acuity in Patients With Age Related Macular Degeneration Completed NCT00329277 Not Applicable
29 Treatment Trial for Acute Central Serous Chorioretinopathy Completed NCT02784665 Not Applicable
30 Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration Completed NCT00879671 Not Applicable
31 A Clinical Study of Fundus Findings in Toxaemia of Pregnancy Completed NCT03076619
32 Mid-term Evaluation of Metamorphopsia in Epiretinal Membrane Surgery Completed NCT03045367
33 Indocyanine Green or Trypan Blue for Delamination of the Internal Limiting Membrane in Macular Hole Surgery Completed NCT00419185 Not Applicable
34 Age-related Normative Values for the Octopus 900 Perimeter Completed NCT01518686 Not Applicable
35 Assessment of Advanced Glaucomatous Visual Field Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL) Completed NCT01372319
36 Efficacy of Over-glasses Patch Treatment for Amblyopia in Children : OPTA Study Completed NCT03080285 Not Applicable
37 Methylphenidate Effect on Humphrey Visual Fields Completed NCT02162381 Not Applicable methylphenidate
38 The Zeaxanthin and Visual Function Study Completed NCT00564902 Not Applicable 3R 3'R Zeaxanthin
39 Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma Completed NCT01209624
40 Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom Completed NCT01012245
41 Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV) Recruiting NCT02829606 Not Applicable
42 Smartphone Flicker Fusion Test for Patients With Optic Disorders. Recruiting NCT03475147 Not Applicable
43 Effect of the Membrane Blue Dual® Dye on the Retinal Sensitivity in Macular Hole Surgery Recruiting NCT02894424
44 Telescope Exchange Study Recruiting NCT03011554 Not Applicable
45 Adenoma Detection Rate With Endocuff-Assisted Colonoscopy - an Italian Trial Recruiting NCT03612674 Not Applicable
46 Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications Recruiting NCT02557451 Not Applicable
47 New Non-invasive Modalities for Assessing Retinal Structure and Function Recruiting NCT03475173 Not Applicable
48 Motivational Interviewing With Focus on Diet and Weight Gain in Pregnant Women With Type 2 Diabetes Active, not recruiting NCT02883127
49 Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Macular Degeneration Enrolling by invitation NCT02747368 Not Applicable
50 Visual Remapping to Aid Reading With Field Loss Not yet recruiting NCT03848663 Not Applicable

Search NIH Clinical Center for Scotoma

Cochrane evidence based reviews: scotoma

Genetic Tests for Scotoma

Anatomical Context for Scotoma

MalaCards organs/tissues related to Scotoma:

42
Eye, Pituitary, Testes, Retina, Endothelial, Cortex, Brain

Publications for Scotoma

Articles related to Scotoma:

(show top 50) (show all 250)
# Title Authors Year
1
Night Blindness, Ring Scotoma, and a Nonrecordable Electroretinogram in an Elderly Woman. ( 30452517 )
2019
2
Acquired unilateral scotoma. ( 28684101 )
2019
3
Visual rehabilitation using microperimetric acoustic biofeedback training in individuals with central scotoma. ( 30253443 )
2019
4
Occipital tip injury with homonymous central scotoma: OCT-NFL and RGC correlation. ( 30766939 )
2019
5
Scotoma in psychiatric practice and research. ( 30774064 )
2019
6
Motion-Induced Scotoma. ( 30799731 )
2019
7
Comparison of pattern electroretinograms of glaucoma patients with parafoveal scotoma versus peripheral nasal step. ( 30837586 )
2019
8
Atypical junctional scotoma secondary to optic chiasm atrophy: a case report. ( 30950119 )
2019
9
Hemicrania Continua Associated with Classic Scintillating Scotoma. ( 29681827 )
2018
10
SCOTOMA CHARACTERISTICS IN MACULAR TELANGIECTASIA TYPE 2: MacTel Project Report No. 7-The MacTel Research Group. ( 28609329 )
2018
11
Central scotoma in tobacco-alcohol toxic optic neuropathy measured with semi-automated kinetic perimetry. ( 29688089 )
2018
12
Central Scotoma after Removal of Silicone Oil in Retinal Detachment: A Multimodal Imaging Case Report. ( 29490394 )
2018
13
Artificial scotoma estimation based on population receptive field mapping. ( 29253656 )
2018
14
Simulation of a central scotoma using contact lenses with an opaque centre. ( 29265475 )
2018
15
Contrast Sensitivity in Eyes with Central Scotoma: Effect of Stimulus Drift. ( 29561506 )
2018
16
A Case of Complete Scotoma Following Intake of Conjugated Linoleic Acid Supplement. ( 29878339 )
2018
17
Sudden paracentral scotoma in a middle-aged male. ( 29930461 )
2018
18
A Middle-aged Woman With Vision Loss and Cecocentral Scotoma. ( 29955763 )
2018
19
Factors associated with the presence of parafoveal scotoma in glaucomatous eyes with optic disc hemorrhages. ( 29973693 )
2018
20
Motion-induced blindness for dynamic targets: Further explorations of the perceptual scotoma hypothesis. ( 30267076 )
2018
21
Scotoma Simulation in Healthy Subjects. ( 30451808 )
2018
22
Central Scotoma After Liver Transplant. ( 30452508 )
2018
23
Macular ganglion cell asymmetry for detecting paracentral scotoma in early glaucoma. ( 30464386 )
2018
24
Stargardt's disease presenting with bilateral central ring scotoma. ( 30581310 )
2018
25
Central Scotoma a Year After Motor Vehicle Crash. ( 30589918 )
2018
26
Comparison of Retinal Vessel Diameter Between Open-Angle Glaucoma Patients With Initial Parafoveal Scotoma and Peripheral Nasal Step. ( 27916714 )
2017
27
The Effects of Nocturnal Dip and Blood Pressure Variability on Paracentral Scotoma in Early Open-Angle Glaucoma. ( 27128963 )
2017
28
Ocular and Systemic Risk Factors of Different Morphologies of Scotoma in Patients with Normal-Tension Glaucoma. ( 28815087 )
2017
29
Homeostatic plasticity in human extrastriate cortex following a simulated peripheral scotoma. ( 28821922 )
2017
30
Retinal Nerve Fiber Layer Defect and Paracentral Scotoma after Internal Limiting Membrane Peeling with a Nitinol Loop. ( 29276228 )
2017
31
Scotoma Visibility and Reading Rate with Bilateral Central Scotomas. ( 28030516 )
2017
32
Predicting the risk of parafoveal scotoma in myopic normal tension glaucoma: role of optic disc tilt and rotation. ( 28282064 )
2017
33
Temporal crescent syndrome vs arcuate scotoma. ( 28318737 )
2017
34
Retinal slippage fold causing a matching contralateral scotoma. ( 28395868 )
2017
35
Usefulness of frequency doubling technology perimetry 24-2 in glaucoma with parafoveal scotoma. ( 28614218 )
2017
36
TEMPORAL THINNING IN SICKLE CELL RETINOPATHY IS ASSOCIATED WITH DIMINISHED PERFUSION ON OCTA AND DENSE SCOTOMA ON MICROPERIMETERY. ( 28644178 )
2017
37
Optic disc drusen: longitudinal aspects, with emphasis on visual field constriction and enlarged blind spot: a retrospective hospital-based clinical series. ( 27646322 )
2017
38
Clinical Clues to Predict the Presence of Parafoveal Scotoma on Humphrey 10-2 Visual Field Using a Humphrey 24-2 Visual Field. ( 26476213 )
2016
39
Long-lasting, dense scotoma under light-adapted conditions in patient with multiple evanescent white dot syndrome. ( 26678272 )
2016
40
Structure-Function Relationship in Glaucoma Patients With Parafoveal Versus Peripheral Nasal Scotoma. ( 26848881 )
2016
41
Progressing Scintillating Scotoma Captured on Automated Visual Field Testing. ( 26854039 )
2016
42
MAPPING THE DENSE SCOTOMA AND ITS ENLARGEMENT IN STARGARDT DISEASE. ( 26909568 )
2016
43
Assessing the GOANNA Visual Field Algorithm Using Artificial Scotoma Generation on Human Observers. ( 27622080 )
2016
44
Characteristics of the preferred retinal loci of better and worse seeing eyes of patients with a central scotoma. ( 27769327 )
2016
45
Optic Disk Pit with Sudden Central Visual Field Scotoma. ( 27872777 )
2016
46
Microperimetry biofeedback training in a patient with bilateral myopic macular degeneration with central scotoma. ( 26265646 )
2015
47
Size of the foveal blue scotoma related to the shape of the foveal pit but not to macular pigment. ( 25449158 )
2015
48
Comparison of risk factors for initial central scotoma versus initial peripheral scotoma in normal-tension glaucoma. ( 25829826 )
2015
49
fMRI of the rod scotoma elucidates cortical rod pathways and implications for lesion measurements. ( 25848028 )
2015
50
Random word recognition chart helps scotoma assessment in low vision. ( 25946100 )
2015

Variations for Scotoma

Expression for Scotoma

Search GEO for disease gene expression data for Scotoma.

Pathways for Scotoma

GO Terms for Scotoma

Cellular components related to Scotoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.55 DNM1L MT-ND4 MT-ND5 OPA1 TMEM126A
2 respiratory chain GO:0070469 9.32 MT-ND4 MT-ND5
3 mitochondrial respiratory chain complex I GO:0005747 9.26 MT-ND4 MT-ND5
4 mitochondrial membrane GO:0031966 9.13 DNM1L MT-ND4 OPA1
5 mitochondrial inner membrane GO:0005743 8.92 MT-ND4 MT-ND5 OPA1 TMEM126A

Biological processes related to Scotoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.61 ABCA4 EYS OPA1
2 response to hypoxia GO:0001666 9.58 KCNMA1 MT-ND4 MT-ND5
3 protein complex oligomerization GO:0051259 9.51 DNM1L OPA1
4 mitochondrial respiratory chain complex I assembly GO:0032981 9.49 MT-ND4 MT-ND5
5 mitochondrial electron transport, NADH to ubiquinone GO:0006120 9.48 MT-ND4 MT-ND5
6 membrane fusion GO:0061025 9.46 DNM1L OPA1
7 mitochondrion morphogenesis GO:0070584 9.37 DNM1L OPA1
8 positive regulation of dendritic spine morphogenesis GO:0061003 9.32 DNM1L OPA1
9 mitochondrial fission GO:0000266 9.26 DNM1L OPA1
10 intracellular distribution of mitochondria GO:0048312 9.16 DNM1L OPA1
11 ATP synthesis coupled electron transport GO:0042773 8.96 MT-ND4 MT-ND5
12 dynamin family protein polymerization involved in mitochondrial fission GO:0003374 8.62 DNM1L OPA1

Molecular functions related to Scotoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADH dehydrogenase (ubiquinone) activity GO:0008137 8.96 MT-ND4 MT-ND5
2 NADH dehydrogenase activity GO:0003954 8.62 MT-ND4 MT-ND5

Sources for Scotoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....